Gal T J, DiFazio C A, Dixon R
Clin Pharmacol Ther. 1986 Nov;40(5):537-42. doi: 10.1038/clpt.1986.220.
In a placebo-controlled, double-blind study we evaluated the ability of a single 50 mg oral dose of nalmefene to block the effects of intravenous opioid challenge (2 micrograms/kg fentanyl). Fentanyl-induced respiratory depression (CO2 responsiveness), analgesia (tourniquet ischemia), and subjective effects were totally blocked for 48 hours and showed only minimal breakthrough 72 hours after nalmefene. Plasma concentration-time data for nalmefene indicate good oral bioavailability and a prolonged terminal elimination phase (mean t1/2 11.1 hours). These findings suggest that nalmefene could provide prolonged effectiveness in limiting emergence of opioid effects during addiction therapy.
在一项安慰剂对照的双盲研究中,我们评估了口服单次50毫克纳美芬阻断静脉注射阿片类药物激发试验(2微克/千克芬太尼)效应的能力。芬太尼诱发的呼吸抑制(二氧化碳反应性)、镇痛(止血带缺血)和主观效应在48小时内被完全阻断,纳美芬给药72小时后仅出现轻微突破。纳美芬的血浆浓度-时间数据表明其口服生物利用度良好,终末消除期延长(平均t1/2为11.1小时)。这些发现提示,在成瘾治疗期间,纳美芬在限制阿片类药物效应出现方面可能具有持久疗效。